#MTaP
Learn about MTAP deficiency and deletion in our FREE on-demand webinar: https://educate.amp.org/local/catalog/view/product.php?productid=600
November 20, 2026 at 2:00 PM
MTAP loss found in 17% of NSCLC by IHC, more often in driver-positive stage IV disease

#LungCancer
MTAP loss found in 17% of NSCLC by IHC, more often in driver-positive stage IV disease
Stephen V Liu summarised a study characterising MTAP loss by immunohistochemistry in non-small cell lung cancer, including lung–lymph node concordance and in vitro PRMT5 inhibition.
lungdaily.org
November 15, 2026 at 12:25 AM
Erasca (#$ERAS) and Bristol Myers Squibb (#$BMY) signed a clinical collaboration to test ERAS-0015 with navlimetostat in MTAP-deleted pancreatic cancer. No combination data yet.

prismmarketview.com/erasca-and-b...
Erasca and Bristol Myers Squibb Partner on Phase 1/2 Pancreatic Cancer Trial
Key Points The trial will pair Erasca’s pan-RAS inhibitor ERAS-0015 with Bristol Myers Squibb’s investigational PRMT5 inhibitor navlimetostat in patien
prismmarketview.com
November 18, 2026 at 3:47 PM
#ERAS Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimet…

https://www.stocktitan.net/news/ERAS/erasca-enters-into-clinical-collaboration-with-bristol-myers-squibb-rnpnr3yqk65g.html?utm_source=stocktitan-bluesky&utm_medium=social
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
Erasca (ERAS) entered a clinical collaboration with Bristol Myers Squibb to evaluate ERAS-0015 in a Phase 1/2 pancreatic cancer trial.The study will test ERAS-0015 with navlimetostat (BMS-986504), Bristol Myers Squibb’s investigational PRMT5 inhibitor, in patients with MTAP-deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the trial, and Erasca will supply ERAS-0015. Both parties will retain development and commercial rights to their respective compounds under the mutually non-exclusive agreement.Erasca said the combination could potentially enhance antitumor activity through simultaneous RAS and PRMT5 inhibition. Nearly all MTAP-deleted pancreatic cancers harbor co-occurring RAS mutations; the planned study will investigate the combination rather than establish a demonstrated treatment benefit.
www.stocktitan.net
November 17, 2026 at 11:40 PM
Rare portia art.. Some new and old art I have done. I tried studying a lil bit of chicano art on some of these :) I love that old school vibe for her.
°
°
°
🎭 #chicana #chicanoart #mtap #mytimeatportia #oc:anam #oc:marisol #oc:biani #builderanam
November 8, 2026 at 9:35 PM
Fanm Nan chienne li pa vo merde, Kay mtap lwe pou li a pa vo merde ...men mwen wi fagget..... Jehovah sou tèt mwen....nèg la di fout li deyó...Nan zón Nan wi....

Yo pa ankouraje heterosexual...yo gen Kay...fè masisi avè yo...madanm ou la ....men ki madanm....tèt mwen ya ye, map atè konyen bouzen...
November 11, 2026 at 1:14 AM
Tango Therapeutics ($TNGX) lost more per share than expected in the third quarter 2026: $0.39, against a -$0.35 estimate. Net loss was $68.4 million.

#stocks #investing #earnings
November 9, 2026 at 1:20 PM
Am I listening to the #mytimeatportia soundtrack while I board my plane back home to #seattle? Maybe.
#mtap #mtas
November 8, 2026 at 3:05 AM
The trial will evaluate vopimetostat with ERAS-0015 in MTAP-deleted pancreatic cancer and MTAP-deleted, RAS-mutant NSCLC.
Tango Therapeutics, Erasca Begin Phase I/II Trial of PRMT5, Pan-RAS Combination
Tango Therapeutics, Erasca Begin Phase I/II Trial of PRMT5, Pan-RAS Combination
ebx.sh
November 5, 2026 at 10:53 PM
Europe and Japan being next is my favorite part of this, it really shouldn’t just be a US story. Would love to see the research around it go global too, like the trial pairing it with vopimetostat for tumors missing MTAP. Lots of people waiting on this one outside the states
November 6, 2026 at 10:48 AM
That last line got me, 5,000 people who probably wouldnt have had much to hope for a year ago. Feels like the first real crack in this disease, and good news is its already being built on with researchers testing daraxonrasib together with vopimetostat for tumors that are missing MTAP
November 6, 2026 at 10:22 AM
Co targeting MTAP deleted pancreatic and lung cancers with this combo is big news. Pairing an oral PRMT5 inhibitor with a pan RAS molecular glue creates a dual attack on tumors. Preclinical tests showing 5x greater potency for ERAS 0015 make this trial one to watch.
November 6, 2026 at 3:34 AM
Breakthrough designation for daraxonrasib with gem/nab-paclitaxel in first-line is big, it moves the RAS approach right up to diagnosis. Fun to watch the chemo-free first-line route too, with #$TNGX planning a Phase 3 of vopimetostat & daraxonrasib for MTAP-deleted tumors
November 5, 2026 at 1:22 AM
$250 million over five years is a serious commitment from PanCAN. Funding like that is how ideas turn into trials, like the one pairing daraxonrasib with vopimetostat for tumors that lost MTAP. All together we can, indeed.
November 4, 2026 at 3:55 AM
Msal , mfè 30 jou atè st doming San benyen, jis Mmonte USA, TICKET MTAP TANN
November 3, 2026 at 10:53 PM
So MTAP loss doesnt just make these tumors lean on PRMT5, it also gets them hooked on branched-chain amino acids. That’s more weak spots in the same subgroup Tango’s vopimetostat & daraxonrasib trial already focuses on. MTAP keeps getting more interesting
November 3, 2026 at 7:39 AM
A pancreatic cancer symposium right in awareness month is perfect timing. Would love to hear what Cambridge researchers make of the latest combo work, like vopimetostat paired with daraxonrasib for tumors missing MTAP. Purple on!
November 3, 2026 at 7:29 AM
The “how each gear works” angle is such a fun way to explain this and a 5th grader version is exactly what most people need. Rasonque’s gear might get a partner soon too, Tango is testing vopimetostat with daraxonrasib to jam a second gear in tumors missing MTAP
November 3, 2026 at 8:00 AM
“A major advance, but not a cure” is such an honest framing. That “not a cure” part is exactly why researchers are already testing pairings, an early trial adds vopimetostat to daraxonrasib for tumors with MTAP deletion to hit a second weak spot. A really encouraging direction
November 2, 2026 at 3:28 AM
MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches. www.mdpi.com/2072-6694/18... #hvhebron #onco [Text complet]
www.mdpi.com
October 29, 2026 at 11:30 AM
Did YOU know that there is a Medical Transportation Assistance Program in Newfoundland and Labrador if you're travelling for medically-necessary treatment or care that is not available close to where you live?
October 28, 2026 at 11:23 AM
The gut bacteria angle is wild, a diet change shifting tumor macrophages enough to help anti-PD-1 work. Pancreatic cancer is getting hit from so many fronts now, from immune studies like this to targeted pairs like the investigational vopimetostat & daraxonrasib combo for MTAP-deleted tumors
October 29, 2026 at 12:28 AM